Anaxirone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206057

CAS#: 77658-97-0

Description: Anaxirone is a synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.

Chemical Structure

img
Anaxirone
CAS# 77658-97-0
Handing Instruction

Theoretical Analysis

MedKoo Cat#: 206057
Name: Anaxirone
CAS#: 77658-97-0
Chemical Formula: C11H15N3O5
Exact Mass: 269.10117
Molecular Weight: 269.2539
Elemental Analysis: C, 49.07; H, 5.62; N, 15.61; O, 29.71

Size Price Shipping out time Quantity
Inquire bulk and customized quantity
Pricing updated 2021-03-06. Prices are subject to change without notice.

Anaxirone, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: Anaxirone; triglycidylurazol; Abbreviation: TGU; Chemical structure: 124triglycidylurazol.

IUPAC/Chemical Name: 1,2,4-tris(oxiran-2-ylmethyl)-1,2,4-triazolidine-3,5-dione

InChi Key: ZTXDHEQQZVFGPK-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H15N3O5/c15-10-12(1-7-4-17-7)11(16)14(3-9-6-19-9)13(10)2-8-5-18-8/h7-9H,1-6H2

SMILES Code: O=C(N1CC2OC2)N(CC3OC3)N(CC4OC4)C1=O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 269.2539 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Holdener EE, Clavel M, Sessa C, ten Bokkel Huinink W, Siegenthaler P, Ludwig C, Klepp O, Renard G, Decoster G, Pinedo HM. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study. Eur J Cancer. 1994;30A(3):394-5. PubMed PMID: 8204365.

2: George M, Scotto V, Carnino F, Dodion P, ten Bokkel Huinink WW, Rotmensz N, Vermorken JB. Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer Clin Oncol. 1987 Jun;23(6):867-9. PubMed PMID: 3653204.

3: Fiebig HH, Henss H, Arnold H, von Bültzingslöwen F, Klee M, Queisser W, Peukert M. Phase II trial of anaxirone in advanced non-small cell lung cancer. Cancer Treat Rep. 1987 May;71(5):539-40. PubMed PMID: 3567979.

4: Schilcher RB, Young JD, Nowrousian MR, Hoffmann B, Schmidt CG. Reversed-phase high-performance liquid chromatographic determination of anaxirone in biological specimens. J Chromatogr. 1986 May 28;378(1):248-53. PubMed PMID: 3733978.

5: Hilgard P, Peukert M, Pohl J. alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent. Cancer Treat Rev. 1984 Jun;11(2):115-20. PubMed PMID: 6498858.

img

Anaxirone



Additional Information